Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Same As
Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Establishes a mandated window of five business days for both Medicaid and private insurers to respond to pre-authorization claims for testing and/or treatments made by physicians on behalf of oncology patients.
Establishes a central business district toll exemption for officers and employees of the city of New York, first responders, physicians, nurses, and people entering the city for medical treatment.
Shortens time frames during which an insurer has to determine whether a pre-authorization request is medically necessary from three business days to three days.
Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Limits availability and coverage for non-invasive prenatal testing for Medicaid patients based on age if such limits are recommended by the United States food and drug administration, the centers for Medicare and Medicaid services, or the United States department of health and human services.
Limits availability and coverage for non-invasive prenatal testing for Medicaid patients based on age if such limits are recommended by the United States food and drug administration, the centers for Medicare and Medicaid services, or the United States department of health and human services.